Safety, Pharmacokinetics, Pharmacodynamics, and Plasma Lipoprotein Distribution of Eritoran (E5564) during Continuous Intravenous Infusion into Healthy Volunteers

Eritoran, a structural analogue of the lipid A portion of lipopolysaccharide (LPS), is an antagonist of LPS in animal and human endotoxemia models. Previous studies have shown that low doses (350 to 3,500 μg) of eritoran have demonstrated a long pharmacokinetic half-life but a short pharmacodynamic...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rossignol, Daniel P., Wasan, Kishor M., Choo, Eugene, Yau, Edwin, Wong, Nancy, Rose, Jeffrey, Moran, Jeffrey, Lynn, Melvyn
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology 2004
Materias:
Pharmacology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC514793/
https://ncbi.nlm.nih.gov/pubmed/15328078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.48.9.3233-3240.2004
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares